GT Biopharma Statistics

Total Valuation

GT Biopharma has a market cap or net worth of $7.29 million. The enterprise value is $4.93 million.

Market Cap	7.29M
Enterprise Value	4.93M

Important Dates

The last earnings date was Thursday, May 15, 2025.

Earnings Date	May 15, 2025
Ex-Dividend Date	n/a

Share Statistics

GT Biopharma has 2.59 million shares outstanding. The number of shares has increased by 50.37% in one year.

Current Share Class	2.59M
Shares Outstanding	2.59M
Shares Change (YoY)	+50.37%
Shares Change (QoQ)	+3.88%
Owned by Insiders (%)	13.45%
Owned by Institutions (%)	8.02%
Float	1.57M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 0.73

Current Ratio	0.73
Quick Ratio	0.65
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -538.87% and return on invested capital (ROIC) is -378.41%.

Return on Equity (ROE)	-538.87%
Return on Assets (ROA)	-131.31%
Return on Invested Capital (ROIC)	-378.41%
Return on Capital Employed (ROCE)	1,347.45%
Revenue Per Employee	n/a
Profits Per Employee	-$11.67M
Employee Count	1
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -10.48% in the last 52 weeks. The beta is 1.39, so GT Biopharma's price volatility has been higher than the market average.

Beta (5Y)	1.39
52-Week Price Change	-10.48%
50-Day Moving Average	2.45
200-Day Moving Average	2.46
Relative Strength Index (RSI)	55.06
Average Volume (20 Days)	109,951

Short Selling Information

The latest short interest is 151,779, so 5.87% of the outstanding shares have been sold short.

Short Interest	151,779
Short Previous Month	36,519
Short % of Shares Out	5.87%
Short % of Float	9.67%
Short Ratio (days to cover)	2.00

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-13.21M
Pretax Income	-9.64M
Net Income	-11.67M
EBITDA	n/a
EBIT	-13.21M
Earnings Per Share (EPS)	-$5.46

Full Income Statement

Balance Sheet

The company has $2.37 million in cash and n/a in debt, giving a net cash position of $2.37 million or $0.91 per share.

Cash & Cash Equivalents	2.37M
Total Debt	n/a
Net Cash	2.37M
Net Cash Per Share	$0.91
Equity (Book Value)	-980,000
Book Value Per Share	-0.39
Working Capital	-980,000

Full Balance Sheet

Cash Flow

Operating Cash Flow	-10.94M
Capital Expenditures	n/a
Free Cash Flow	-10.94M
FCF Per Share	-$4.23

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

GT Biopharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-50.37%
Shareholder Yield	-50.37%
Earnings Yield	-160.03%
FCF Yield	-150.03%

Analyst Forecast

The average price target for GT Biopharma is $11.00, which is 290.07% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$11.00
Price Target Difference	290.07%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on February 5, 2024. It was a reverse split with a ratio of 0.0333333:1.

Last Split Date	Feb 5, 2024
Split Type	Reverse
Split Ratio	0.0333333:1

Scores

Altman Z-Score	n/a
Piotroski F-Score	1